Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation TCT 2017

BioNIR: Specifications and BIONICS/NIREUS Results in Perspective

Presenter: Stephen G. Ellis, David E. Kandzari

October 30, 2017

Presentation TCT 2017

Resolute and Onyx Zotarolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Presenter: Stephen G. Ellis, David E. Kandzari, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Presenter: Stephen G. Ellis, David E. Kandzari, Sigmund Silber

October 30, 2017

Presentation TCT 2017

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Presenter: Stephen G. Ellis, David E. Kandzari, Tullio Palmerini

October 30, 2017

Presentation TCT 2017

Metallic DES: What Can We Expect From New Drugs, Polymers, and Metals? Have We Reached the Limit of Iterative Development?

Presenter: Dean J. Kereiakes, Spencer B. King III, Elazer R. Edelman

October 30, 2017

News Opinion Editor's Corner

Q&A: Juan Granada Takes the Helm at the Cardiovascular Research Foundation

Shelley Wood

September 12, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

Advertisement

BioNIR: Specifications and BIONICS/NIREUS Results in Perspective

Resolute and Onyx Zotarolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Metallic DES: What Can We Expect From New Drugs, Polymers, and Metals? Have We Reached the Limit of Iterative Development?

Q&A: Juan Granada Takes the Helm at the Cardiovascular Research Foundation

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content